Replies to post #381114 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

" It stands to reason that if it works very well in the lab against Covid, that it will also work in the human body against Covid"

No, it doesn't. There are literally dozens of compounds that work excellently against COVID 19 in vitro, but don't work at all in vivo.

And there is remdesivir, with an SI of over 1000 (brilacidin is a mere 426) that has marginal efficacy at best.

Lots of chickens being counted when the rooster is probably infertile.

[crashco]

Agreed. It is the body of evidence that has been amassed by Innovation Pharmaceuticals that is generating excitement.

Taking B into phase II along multiple therapeutic paths (OM, IBD, antibiotic, antiviral) was primarily designed to secure the bona fides of B and strengthen negotiating position for the platform without incurring the massive cost of a phase III trial.

The secondary benefit of the platform strategy has been the slow build up of confidence among investors. Longs have held and accumulated. Others have marked their calendar and timed their entry. Few, if any, will cut and run before TL results. Buying will dominate the chart until phase II results are known.

After? I've always held that a deal would define the baseline share price and not market makers or market sentiment.
Multiple BP bidding on the potential revenues of the Brilacidin platform will set the new baseline share value. Market sentiment will shape dips and peaks afterward.

EDIT: Lock Confirmed. http://www.ipharminc.com/press-release/2021/11/3/database-lock-completed-for-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19

A trigger for increased investor entry. Volume will continue to increase.